Xencor, Inc Contract Liability (Deferred Revenue)
Xencor, Inc (XNCR) had Contract Liability (Deferred Revenue) of $0 as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2025-02-27
- 2024-12-31: Contract with Customer, Liability, Current $0.00.
- 2024-09-30: Contract with Customer, Liability, Current $0.00.
- 2024-06-30: Contract with Customer, Liability, Current $0.00.
- 2024-03-31: Contract with Customer, Liability, Current $0.00.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-27 | |
| 2024-09-30 | $0.00 10-Q/A · filed 2025-02-24 | |
| 2024-06-30 | $0.00 10-Q/A · filed 2025-02-24 | |
| 2024-03-31 | $0.00 10-Q/A · filed 2025-02-24 | |
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 | |
| 2023-09-30 | $9.20M 10-Q/A · filed 2025-02-24 | $9.22M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $7.90M 10-Q/A · filed 2025-02-24 | $7.87M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $30.10M 10-Q/A · filed 2025-02-24 | $30.10M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $30.30M 10-K · filed 2025-02-27 | $30.32M 10-K · filed 2023-02-27 |
| 2022-09-30 | $35.20M 10-Q · filed 2023-11-08 | $35.19M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $35.30M 10-Q · filed 2023-08-03 | $35.30M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $35.49M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $37.29M 10-K · filed 2023-02-27 | |
| 2021-09-30 | $12.95M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $19.20M 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $77.82M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $92.61M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $43.84M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $44.69M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $46.18M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $45.20M 10-K · filed 2021-02-24 | |
| 2019-09-30 | $45.60M 10-Q · filed 2020-11-06 | $45.58M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $45.50M 10-Q · filed 2020-08-05 | $45.48M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $59.24M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $40.08M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $40.08M 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $60.12M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $60.12M 10-Q · filed 2018-05-07 | |
| 2017-12-31 | $60.12M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |